RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Blood

• Publication date

  2008-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2007-07-099366PMID 17978170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

  2008cited by this paper
• A neoepitope generated by an FLT 3 internal tandem duplication ( FLT 3-ITD ) is recognized by leukemia-reactive autologous CD 8 T cells

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

  2007cited by this paper
• A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells.

  2007cited by this paper
• Acute myeloid leukaemia.

  2006cited by this paper
• Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

  2006cited by this paper
• Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

  2006cited by this paper
• Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.

  2006cited by this paper
• Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.

  2006cited by this paper
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

  2006cited by this paper
• Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

  2005cited by this paper
• Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.

  2005cited by this paper
• Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.

  2005cited by this paper
• Immunogenicity of Bcl-2 in patients with cancer.

  2005cited by this paper
• Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation

  2005cited by this paper
• Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

  2004cited by this paper
• mRNA expression of leukemia‐associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies

  2004cited by this paper
• Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

  2004cited by this paper
• Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia.

  2004cited by this paper
• Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.

  2003cited by this paper
• Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.

  2003cited by this paper
• Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.

  2003cited by this paper
• Antigen‐specific immunotherapy and cancer vaccines

  2003cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Characterization of several leukemia‐associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia

  2003cited by this paper
• Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

  2003cited by this paper
• Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial

  2003cited by this paper
• Vaccination of patients with solid tumours.

  2003cited by this paper
• Serum test for assessment of patients with Bence Jones myeloma.

  2003cited by this paper
• CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.

  2002cited by this paper
• Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.

  2002cited by this paper
• The World Health Organization (WHO) classification of the myeloid neoplasms.

  2002cited by this paper
• Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis

  2001cited by this paper
• Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

  2000cited by this paper
• Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

  2000cited by this paper
• The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.

  1999cited by this paper
• A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens

  1998cited by this paper
• Acute myeloid leukaemia.

  1996cited by this paper
• Mutations and promoter methylation status of NPM1 in myeloproliferative disorders

  1996cited by this paper
• Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation.

  1995cited by this paper

• The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies

  2025influential citation
• JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025

  2025cites this paper
• HMMR in human cancers: regulatory mechanism and biological function

  2025cites this paper
• Advances and challenges in anti-cancer vaccines for multiple myeloma

  2024cites this paper
• New insights into the mechanisms of the extracellular matrix and its therapeutic potential in anaplastic thyroid carcinoma

  2024cites this paper
• Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics

  2024cites this paper
• FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

  2024cites this paper
• Vaccines: a promising therapy for myelodysplastic syndrome

  2024cites this paper
• iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens

  2024cites this paper
• Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia

  2024cites this paper
• AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients

  2024cites this paper
• Senescent T Cells: The Silent Culprit in Acute Myeloid Leukemia Progression?

  2024cites this paper
• Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor–positive Breast Cancer

  2024cites this paper
• Breaking Boundaries: Immunotherapy for Myeloid Malignancies

  2024cites this paper
• The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches

  2022cites this paper
• Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?

  2022cites this paper
• Tumor-Tissue Expression of the Hyaluronic Acid Receptor RHAMM Predicts Histological Transformation in Follicular Lymphoma Patients

  2022cites this paper
• Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.

  2022cites this paper
• Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes

  2022cites this paper
• Research progress on dendritic cell vaccines in cancer immunotherapy

  2022cites this paper
• Increasing Role of Targeted Immunotherapies in the Treatment of AML

  2022cites this paper
• Immunotherapy for the treatment of multiple myeloma

  2022influential citation
• The importance of RHAMM in the normal brain and gliomas: physiological and pathological roles

  2022cites this paper
• RHAMM-Target Peptides Inhibit Proliferation and Viability of Cancer Cells

  2021cites this paper
• High Expression of Hyaluronan-Mediated Motility Receptor Predicts Adverse Outcomes: A Potential Therapeutic Target for Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia

  2021cites this paper
• WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS

  2021cites this paper
• Survivin’ Acute Myeloid Leukaemia—A Personalised Target for inv(16) Patients

  2021cites this paper
• Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma

  2021cites this paper
• Vaccination as Immunotherapy in Hematologic Malignancies.

  2021cites this paper
• HMMR  is a prognostic-related biomarker of p ancreatic ductal adenocarcinoma  and promotes the development of  p ancreatic ductal adenocarcinoma

  2021cites this paper
• 4-Methylumbelliferone induces antitumor effects independently of hyaluronan synthesis inhibition in human acute leukemia cell lines.

  2021cites this paper
• Immunotherapy in Acute Myeloid Leukemia: Where We Stand

  2021cites this paper
• Extracellular matrix and its therapeutic potential for cancer treatment

  2021cites this paper
• RHAMM-Target Peptides as Molecular Imaging Probes for the Imaging of RHAMM-Expressing Cancer Cells

  2021cites this paper
• Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia

  2021cites this paper
• Antitumor Effects of RHAMM-Target Peptides on Prostate Tumor Xenografts in Nude Mice

  2020cites this paper
• Actors on the Scene: Immune Cells in the Myeloma Niche

  2020cites this paper
• Immunotherapeutic Strategies for Multiple Myeloma

  2020cites this paper
• WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML)

  2020cites this paper
• Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition

  2020cites this paper
• Cellular Immunotherapy for Multiple Myeloma

  2019cites this paper
• The Important Role of Immunotherapies in Acute Myeloid Leukemia

  2019cites this paper
• Antigen Targets for the Development of Immunotherapies in Leukemia

  2019cites this paper
• In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma

  2019cites this paper
• HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells

  2019cites this paper
• Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?

  2019cites this paper
• Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation

  2019cites this paper
• Impact of monocyte differentiation and intracellular infection on processing and presentation of autoantigen

  2018cites this paper
• Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth

  2018cites this paper
• Novel Approaches to Acute Myeloid Leukemia Immunotherapy

  2018cites this paper
• Immune surveillance by autoreactive CD4‐positive helper T cells is a common phenomenon in patients with acute myeloid leukemia

  2018cites this paper
• Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance

  2018cites this paper
• Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.

  2018cites this paper
• Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders

  2018cites this paper
• Myeloid Leukemia Vaccines

  2018cites this paper
• A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia

  2018cites this paper
• Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’

  2018cites this paper
• Cellular immunotherapy as a therapeutic approach in multiple myeloma

  2018cites this paper
• Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

  2018cites this paper
• Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects

  2018cites this paper
• Title Recent advance in antigen-specific immunotherapy for acutemyeloid leukemia

  2018cites this paper
• The Development Of Platforms For Inhibiting RHAMM-HA Interactions & The Development Of An Optical Probe For Measuring Glomerular Filtration Rate

  2018cites this paper
• Peptide-based vaccines

  2018cites this paper
• Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach

  2018cites this paper
• Title Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia

  2018cites this paper
• Design of peptide mimetics to block pro-inflammatory functions of HA fragments.

  2018cites this paper
• 10 Hyaluronan Associated Inflammation and Microenvironment Remodelling Influences Breast Cancer Progression

  2018cites this paper
• In vitro generation of cytotoxic T cells with potential for adoptive tumour immunotherapy

  2017influential citation
• Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.

  2017cites this paper
• Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment

  2017cites this paper
• Hematopoietic stem cell transplantation and cellular therapy

  2017cites this paper
• The progress and current status of immunotherapy in acute myeloid leukemia

  2017cites this paper
• Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors

  2017cites this paper
• Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

  2017cites this paper
• Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia

  2017cites this paper
• Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses

  2017cites this paper
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

  2016cites this paper
• The T Cell in Myeloma.

  2016cites this paper
• Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

  2016cites this paper
• HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

  2016cites this paper
• Versican vs versikine: tolerance vs attack.

  2016cites this paper
• Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation.

  2016cites this paper
• ROS: novel regulators of thrombopoiesis.

  2016cites this paper
• Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.

  2016cites this paper
• Renewing the immunological approach to AML treatment: from novel pathways to innovative therapies

  2016cites this paper
• The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells

  2016cites this paper
• Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial

  2016cites this paper
• Carcinoma Cell Hyaluronan as a "Portable" Cancerized Prometastatic Microenvironment.

  2016cites this paper
• Immune Therapies in Multiple Myeloma

  2016cites this paper
• T cell‐based targeted immunotherapies for patients with multiple myeloma

  2015influential citation
• The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

  2015cites this paper
• Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer

  2015cites this paper
• Role of Immune Therapies for Myeloma.

  2015cites this paper
• Antigen-specific immunotherapies for acute myeloid leukemia.

  2015cites this paper
• Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy

  2015cites this paper
• Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies

  2015cites this paper
• Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.

  2015cites this paper
• Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemias

  2015cites this paper
• Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies

  2015cites this paper